SecBot SecBot
PRESS-RELEASE ·Filed Jun 25, 2026

HCM

HUTCHMED (China) Limited
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong efficacy and manageable safety profile, combined with priority review, suggest a high likelihood of NMPA approval. Traders should monitor the NMPA decision timeline and any updates on global development plans. The ESMO GI presentation on July 4, 2026, may provide additional detail and investor attention.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.17
T+0 close · Jun 26, 2026 · via day close
Latest settled
+38.35%
T+60 · $14.07
Vs SPY
+32.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 26 $10.17entry
  2. T+1 · 5mo ago +5.31%α +3.66% · $10.71
  3. T+5 · 4mo ago +14.55%α +11.49% · $11.65
  4. T+20 · 4mo ago +9.34%α +7.96% · $11.12
  5. T+60 · 8w ago +38.35%α +32.26% · $14.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma (ICC), with an IRC-assessed ORR of 42.5% and median OS of 16.6 months. The NDA has been accepted and granted priority review by China's NMPA, positioning fanregratinib as a potential new treatment option in a targeted ICC population.

Key Facts

  • Pivotal Phase II study met primary endpoint with IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%) in advanced ICC patients with FGFR2 fusions/rearrangements.
  • Median progression-free survival (PFS) was 6.9 months; median overall survival (OS) was 16.6 months.
  • NDA for fanregratinib in this indication accepted and granted priority review by China's NMPA in December 2025.
  • Drug-related Grade 3+ adverse events occurred in 48.3% of patients; treatment discontinuation due to AEs was only 2.2% with no treatment-related deaths.
  • Fanregratinib is a novel, selective FGFR 1/2/3 inhibitor; HUTCHMED retains worldwide rights.

Financial Impact

Positive Phase II data and priority review status support potential approval in China, expanding HUTCHMED's oncology portfolio. Fanregratinib addresses a niche but high-unmet-need ICC population; peak sales potential not disclosed but could be material given orphan-like indication.

pipeline valueregulatory probability of successfuture revenue potential

Risk Factors

  • Competition from approved FGFR inhibitors (pemigatinib, infigratinib) in similar indications.
  • Grade 3+ AE rate of 48.3% may raise safety concerns despite low discontinuation.
  • Commercial success depends on pricing, reimbursement, and physician adoption in China.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3317235

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026